logo ecco
Portal

Search

Poster presentations: Clinical: Therapy and Observation 2021

P510 Postoperative enterocoutaneous fistula after surgery for Crohn’s disease performed in a tertiary centre over 15 years: analysis of the long-term outcomes and predictors of fistula closure

P511 Disease-specific risk factors for malnutrition development in IBD

P512 Safety of reduced clinical monitoring in patients with stable Inflammatory Bowel Disease on maintenance thiopurine therapy

P513 Assessment of quality indicators in The Swedish Inflammatory Bowel Disease Registry (SWIBREG) for Crohn’s Disease treated with biological therapies

P514 Influence of the frequency of glucocorticosteroid therapy courses on the hormonal resistance in patients with ulcerative colitis.

P515 A 12-week tailored physical training program including dietary advice in children with Inflammatory Bowel Disease: a randomized crossover trial

P516 Serological biomarkers of tissue remodeling are associated with endoscopic remission in Crohn’s disease patients treated with GED-0301 (mongersen)

P517 One year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicentre real-world study from Italy.

P518 Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID.

P519 Impact of skin examination prior to initiation of biological treatment in patients with Inflammatory Bowel Disease: preliminary data

P520 ‘Eetscore’ in patients with Inflammatory Bowel Disease: an online tool to assess diet quality and provide personalised dietary advice

P521 Correlation between physician disease assessment in Ulcerative Colitis and burden of disease: ICONIC 2-year data of 120 patients in Turkey

P522 Effectiveness of tofacitinib in a real-world Israeli cohort of patients with moderate-severe ulcerative colitis

P523 Survey to identify patient characteristics, treatment preferences and impact of inflammatory bowel disease (IBD) on quality of life across 7 countries in Europe

P524 Endoscopic dilations of intestinal stenosis in Crohn's disease

P525 Patients' Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Di

P526 Social functioning, work-productivity and psychological assessment in a cohort of patients with inflammatory bowel disease: an observational study

P527 Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry

P528 Reducing intravenous monoclonal antibody observation times without compromising patient safety; a single-centre observational study.

P529 Adalimumab persistence and its biosimilar in inflammatory bowel disease: experience in a tertiary centre

P530 Proactive therapeutic drug monitoring of anti-TNF agents is associated with higher mucosal healing rates in Crohn's disease

P531 SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study.

P532 Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic

P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice

P534 has been withdrawn

P535 Optimising vedolizumab in treatment sequences for Crohn’s disease: Results from a simulation model using real-world evidence

P536 Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease.

P537 Anemia in Crohn's Disease: Response to treatment and risk of recurrence

P538 The reliability of patient performed fecal calprotectin testing

P539 Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)

P540 Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literature

P541 Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown.

P542 Clinical presentation, disease behavior and management of inflammatory bowel disease at extremes of age

P543 The role of social support on psychological distress and health-related quality of life in adults with mild to moderately active Crohn's disease.

P544 Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrations

P545 Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with Vedolizumab

P546 The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype

P547 Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysis

P548 Drug Survival in Patients with Inflammatory Bowel disease: An observational study

P549 Changing Lanes: Switching Therapies in Inflammatory Bowel Disease, An Observational Study.

P550 Short term effects of a combined lifestyle intervention in patients with Inflammatory Bowel Disease

P551 Lack of adherence to infliximab in inflammatory bowel disease patients contributes to loss of response in Crohn’s disease.

P552 Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.

P553 Factors related to steroid consumption in IBD patients: Evidence from a multicenter Study

P554 Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?

P555 Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel disease

P556 Safety and efficacy of ustekinumab in the treatment of Crohn's Disease: A systematic review and meta-analysis

P557 Long-term outcomes following laparoscopic ileocecal resection without any residual lesion for Crohn’s disease: a single-center observational study

P558 Medication Preference of 400 patients with mild to moderate Ulcerative Colitis

P559 Efficacy of Ustekinumab in the treatment of patients with Crohn’s disease with failure to previous conventional or biologic therapy: an observational real-life study

P560 Clinical outcomes of vedolizumab maintenance treatment for Korean patients with inflammatory bowel disease who failed anti-TNF therapy: A KASID prospective multicenter cohort study

P561 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo Endoscopic Score (MES) in predicting the therapeutic effect of mesalazine in UC patients.

P562 Web-based questionnaire survey about self-management for patients with Inflammatory Bowel Disease in Japan

P563 Comparison of long-term outcomes of infliximab with adalimumab in biologic naïve patients with Crohn’s disease: a tertiary referral center 13-year experience.

P564 Validation of the IBD-Disk instrument in a Portuguese cohort

P565 Illness perception as a clinical tool to detect mood disturbances (anxiety or depression) in inflammatory bowel disease patients.

P566 Impact of induction therapy and clinical remission on resting energy expenditure in children with Crohn’s Disease

P567 Pharmacist-managed immunomodulator clinic in titration and monitoring of immunosuppressants in Inflammatory Bowel Disease

P568 Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn’s disease.

P569 Online education significantly improved gastroenterologists' knowledge of management strategies and treatment options for ulcerative colitis.

P570 Prediction of achieving remission in Crohn's disease patients by abdominal Imaging

P571 Optimal biologic management of endoscopic postoperative recurrence following ileocecal resection in Crohn’s disease

P572 The influence of beliefs about medication in therapeutic adherence among patients with inflammatory bowel disease.

P573 Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

P574 Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study

P575 Nutrition and Inflammatory Bowel Disease – a nationwide survey of patients, gastroenterologists and dietitians

P576 Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients.

P577 Withdrawal of thiopurines in patients with Ulcerative Colitis in remission

P578 Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients

P579 Online Education Significantly Improved Gastroenterologists' Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis

P580 Benchmarking IBD Pharmacy Services to optimise, strengthen and align IBD Expert Pharmacy Practice

P581 Pre-operative prolonged antibiotic treatment in ileocecal Crohn’s disease: single center non-randomized prospective study.

P582 Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure

P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study

P584 Mucosal Eosinophilia is an Independent Predictor of Vedolizumab Effectiveness in Ulcerative Colitis

P585 IBD Reference and Biosimilar adalimumab CroSS over Study (iBaSS): a mixed methods clinical trial of patients transitioning between originator and biosimilar adalimumab. Qualitative findings from an interim analysis presenting the patient perspective.

P586 Drug-induced lipid changes in patients with Inflammatory Bowel Disease: a single center, prospective study

P587 Utility of intestinal ultrasound in Inflammatory Bowel Disease patients on management decisions

P588 Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients

P589 Stable Trends in Radiation Exposure Amongst Patients with a New Diagnosis of Inflammatory Bowel Disease at an Irish Tertiary Referral Hospital

P590 Which biomarkers have an effect on therapeutic vedolizumab drug levels? A retrospective analysis from a London Tertiary Centre.

P591 Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB).

P592 Costs savings associated with ferric maltol and the reduced use of intravenous iron based on real world data

P593 Ustekinumab for the treatment of perianal Crohn’s disease. A real-world experience in a Spanish hospital

P594 Utilisation of anti-TNF agents in phlegmonous Crohn’s disease: an Australian tertiary referral centre experience

P595 Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease

P596 Trough concentration of ustekinumab was a useful biomarker for the prediction of treatment-effects in patients with Crohn’s Diseases.

P597 Cycling Anti-TNF Therapy in Inflammatory Bowel Disease: Effectiveness and Durability of Switching from adalimumab to infliximab

P598 Previous Intestinal Resection Is Associated with Postoperative Complications in Crohn’s Disease: A Cohort Study

P599 Perspectives on disease- and treatment-related issues encountered by patients with Inflammatory Bowel Disease: a qualitative concept mapping study

P600 Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study

P601 Are Inflammatory Bowel Disease patients’ expectations met by dietetic services?

P602 Vedolizumab subcutaneous influencing disease course in Constant-care app solution

Portal